Elixir Medical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - Cx Registry

Study Overview
=================
Brief Summary
-----------------
This additional arm of the DESolve Nx study is an evaluation of the CE Mark approved DESolve Cx Novolimus Eluting Bioresorbable Scaffold System.

Detailed Description
-----------------
The DESolve Cx Single-Arm Registry enrolled patients using the same inclusion and exclusion criteria and clinical endpoints as the DESolve Nx Study This study was split into 2 cohorts - European and Brazilian. The European cohort (30 subjects) completed all follow-up at 1 year and the Brazilian cohort at 3 years (20 subjects)

Official Title
-----------------
Non-randomized Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System in de Novo Native Coronary Artery Lesions - DESolve Cx Single-Arm Registry

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: DESolve Cx drug eluting coronary scaffold system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient must be at least 18 years of age and for the 35-patient subset, patients must be over the age of 50 Patient is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System (BCSS) and he/she provides written informed consent, as approved by the appropriate Ethics Committee of the respective clinical site, prior to any clinical study related procedure Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or electrocardiogram (ECG) changes consistent with ischemia) Patient must be an acceptable candidate for coronary artery bypass graft (CABG) surgery Patient must agree to undergo all clinical study required follow-up visits, angiograms, and as applicable, imaging testing Patient must agree not to participate in any other clinical study for a period of two years following the index procedure Target lesion must be located in a native coronary artery with a nominal vessel Not part of a clinical investigation Treatment of a single, non-target lesion located in a separate major epicardial vessel Target vessel diameter must be a diameter of between 2.25 and 3.5 mm assessed by online QCA Target lesion must measure ≤ 24 mm in length Target lesion must be in a major artery or branch with a visually estimated stenosis of ≥ 50% and < 90% with a TIMI flow of ≥ 1 Target vessel must be in a major coronary artery or major branch Exclusion Criteria: Patient has a known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure and cardiac enzymes have not returned within normal limits at the time of procedure Patient is currently experiencing clinical symptoms consistent with AMI Patient requires the use of any rotablator intervention during the index procedure Patient has current unstable arrhythmias Patient has a known left ventricular ejection fraction (LVEF) < 30% Patient has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant Patient is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after the procedure Patient is receiving immunosuppression therapy and has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.) Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that cannot be stopped and restarted according to local hospital standard procedures. Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, both clopidogrel and ticlopidine, Novolimus, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected liver disease. Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL, or patient on dialysis) Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months Patient has had a significant GI or urinary bleed within the past six months Patient has extensive peripheral vascular disease that precludes safe 6 French sheath insertion Patient has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year) Patient is already participating in another clinical study Women of childbearing potential who have not undergone surgical sterilization or are not post-menopausal (defined as amenorrheic for at least one year) as well as women who are pregnant or nursing Patient is unable to give their consent, is legally incompetent, or is institutionalized by virtue of an order issued by the courts or other authority Target lesion(s) meets any of the following criteria: Aorto-ostial location Left main location Located within 5 mm of the origin of the LAD or LCX Located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft Lesion involving a side branch >2mm in diameter or bifurcation Previous placement of a scaffold proximal to or within 10 mm of the target lesion Total occlusion (TIMI flow 0), or TIMI flow < 1 Excessive tortuosity proximal to or within the lesion Angulation (≥ 45o) proximal to or within the lesion Calcification moderate or heavy Previous intervention restenosis The target vessel contains visible thrombus Another clinically significant lesion (>40%) is located in the same major epicardial vessel as the target lesion Patient has a high probability that a procedure other than pre-dilatation and scaffolding and (if necessary) post-dilatation will be required at the time of index procedure for treatment of the target vessel (e.g. atherectomy, cutting balloon or brachytherapy)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: single arm
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: DESolve Cx<br>DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System | Device: DESolve Cx drug eluting coronary scaffold system<br>* percutaneous coronary intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinically-indicated Major Adverse Cardiac Events | Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to the European and Brazilian Cohorts | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-scaffold Late Lumen Loss by Quantitative Coronary Angiography (QCA) | quantitative QCA measurement of change in the lumen diameter from post procedure and 6 months which is described as late lumen loss This applies to both the European and Brazilian Cohorts | 6 months | 
| Clinically-indicated Major Adverse Cardiac Events (MACE) | Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to both the European and Brazilian Cohorts | 12 months | 
| Clinically-Indicated Major Adverse Cardiac Events | Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This time point applies to the Brazilian Cohort only | 24 months | 
| Clinically-indicated Major Adverse Cardiac Events | Number of Participants with one or more Clinically-indicated Major Adverse Cardiac Events This applies to the Brazilian Cohort only | 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biorersorbable scaffold, drug eluting, novolimus